TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Strategies in Patients Undergoing Repeat AF Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: All patients undergoing first redo AF ablation who have chronically isolated pulmonary veins and no non-PV triggers with provocation testing (randomized intra-procedure).~Exclusion Criteria:~1. Patients in whom ≥1 PVs have reconnected and AF triggers can be elicited from the reconnected PV.~2. Patients who demonstrated non-PV triggers for AF.~3. Patients who have experienced arrhythmia recurrence post ablation where the recurrent arrhythmia is other than atrial fibrillation or typical atrial flutter~4. Failure to obtain informed consent~5. Patients with a mechanical mitral valve

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CTI/AAD (control) (Type: EXPERIMENTAL): In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 1- Cavo-tricuspid isthmus (CTI) ablation with adjustment and/or optimization of antiarrhythmic drug regimen where possible (control arm)
- Posterior wall isolation (Type: EXPERIMENTAL): In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 2-LA Posterior wall isolation by creation of a LA roof and floor line
- Empiric Isolation of common trigger sites (Type: EXPERIMENTAL): In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 3-empiric ablation of common sites of non-PV triggers of AF in both the right and left atria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must have histologically or cytologically confirmed WT NSCLC that is stage IV / metastatic or recurrent~2. Participants with tumor tissue high expression of PD-L1 as defined by Tumor Proportion Score (TPS) ≥ 50%~3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~4. Participants with measurable disease by spiral CT or MRI per RECIST v.1.1 criteria.~5. Participants that have completed prior radiotherapy or radiosurgery at least 2 weeks prior to randomization.~6. Participants must be naïve to therapy for the advanced stage of the disease. Previous neoadjuvant or adjuvant therapy is allowed for participants who successfully underwent complete radical surgery and ONLY if the last treatment was administered more than 12 months prior to the start of the trial treatment~Exclusion Criteria:~1. Participants with active central nervous system (CNS) metastases or carcinomatous meningitis~2. Participants with any serious or uncontrolled medical disorder or active infection with the hepatitis virus or the human immunodeficiency virus (HIV)~3. Participants with Grade 1 (NCI-CTCAE v.4.03) toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue prior to randomization~4. Participants that have received pembrolizumab~5. Participants with a history of severe hypersensitivity reactions to monoclonal antibodies~6. Pregnant or lactating women~7. Participants receiving any investigational agent within 28 days of first administration of trial treatment~8. Participants that have received therapy with anti-tumor vaccines or other immunostimulatory antitumor agents~9. Participants that have received therapy with anti-PD-1, anti-PD-L1, anti-PD-L-2, anti-CD-137, and/or anti CTLA-4 antibodies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pegilodecakin + Pembrolizumab (Type: EXPERIMENTAL): Participants received pegilodecakin subcutaneously (SQ) at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (\>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Pembrolizumab administered as an intravenous (IV) infusion at 200 mg on Day 1 of a 21-day cycle.
- Pembrolizumab (Type: ACTIVE_COMPARATOR): Participants received pembrolizumab as an IV infusion at 200 mg on Day 1 of a 21-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient admitted in an Ebola Treatment Center (ETC) or Ebola Transit Center (TC)~* Laboratory-confirmed (Ebola RT-PCR positive result) EVD diagnosis, or, EVD suspect patient requiring instant intravenous antibiotic treatment~* Willing and able to provide written informed consent personally or by a legally acceptable representative if the patient is unable to do so~Exclusion Criteria:~* We do not exclude certain patient groups, but whenever harm is expected from the additional blood sampling needed for this study, the clinician can opt not to enroll the patient

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~* Written informed consent must be obtained from all participants prior to beginning therapy (participants should have the ability to understand be willing to sign a written informed consent document)~* Individuals with oropharyngeal, hypopharyngeal, or laryngeal cancer of Stages I-IV undergoing radiation and chemo therapies at Wake Forest Baptist Medical Center~* Participants will have surgically received no more than selective neck dissection and tumor biopsy (participants who have undergone primary tumor resection or radical neck dissection will not be eligible)~* Participants must have completed a minimum of third grade education in order to answer questions of the quality of life survey~* Participants must be willing to participate in the swallowing exercise program~Exclusion~* Medical history of cerebrovascular accident, Parkinson's disease, any type of dementia, myasthenia gravis, or amyotrophic lateral sclerosis~* Previous radiation treatment for head/neck cancer~* Swallowing problem of etiology other than current lesion~* Pregnant women are not anticipated in the patient population, but would be excluded from participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Early exercise group) (Type: EXPERIMENTAL): Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
- Arm II (Late exercise group) (Type: EXPERIMENTAL): Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed multiple myeloma, Stage II-III as per Salmon and Durie (1975)~* Indication for biphosphonate therapy~Exclusion Criteria:~* Previous therapy with ibandronate or zoledronate within the past 12 months~* Renal insufficiency with serum creatinine \>3.0 mg/dL or \>265 micromoles per liter (µmol/L) or CrCl \<30 mL/min~* Hypersensitivity to ibandronate, zoledronate, or other biphosphonates~* Presence of secondary malignomas, apart from basaliomas and cervical carcinoma in situ~* Severe accompanying illness with organ impairment~* Osteonecrosis of the jaw at the start of the study~* Life expectancy ≤12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibandronate (Type: EXPERIMENTAL): Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
- Zoledronate (Type: ACTIVE_COMPARATOR): Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness and Cognition in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizophrenia (men only)~* aged 18-55~* with no change in antipsychotic medication and clinical status within four weeks prior to the study~* affiliates or entitled to a social security scheme~* who have given their informed consent before participating in the study.~Exclusion Criteria:~* History of head trauma, neurological disease or not stabilized serious physical illness~* Disorders related to the use of a psychoactive substance, as defined by the DSM-IV (abuse, dependence or withdrawal) within 6 months~* Beta blocking and anti-arrhythmic medications.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Mindfulness (Type: EXPERIMENTAL): Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month.
- Control (Type: NO_INTERVENTION): Patient will have usual medical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be at least 19 years of age and older~* Ability to give informed consent and attend the study visits~* Patients with established diagnosis of retinal vascular diseases (diabetic macular edema, neovascular macular degeneration,presumed ocular histoplasmosis syndrome, high myopia) who require intravitreal injection of anti-VEGF drugs such as bevacizumab,ranibizumab or aflibercept and are likely to need three monthly doses.~* Patients who have not received intravitreal injections within 3 months of study entry~* No previous established diagnosis of glaucoma and consequently no previous history of Argon Laser Trabeculoplasty (ALT) or Selective Laser Trabeculoplasty (SLT).~* No previous history of ocular surgery~* Patients who are not planning on and are unlikely to require an elective ocular surgical or laser procedure within the study duration~* Open angle of the anterior chamber on clinical examination~* Ability to cooperate for aqueous humor dynamic studies~* Contact lenses removed prior to topical fluorescein instillation, and not used until the end of each fluorophotometry session~* Able to participate on site over the multi-visit study period~Exclusion Criteria:~* Age less than 18 years of age~* Women who are pregnant or nursing~* Ocular hypertension or glaucoma~* Narrow angle with complete or partial closure (gonioscopy angle \<2)~* Any previous surgical or laser procedures~* Secondary glaucoma including pigmentary, exfoliative, uveitic and traumatic glaucomas~* Any active neovascularization of the iris, angle, disc or retina~* Diagnosis of retinal arterial or vein occlusion~* Chronic or recurrent inflammatory eye disease~* Ocular trauma within the past 6 months~* Ocular infection or ocular inflammation in the past 2 months~* Any abnormality preventing reliable fluorophotometry of either eye,such as corneal scarring or severe dry eye that results in punctuate fluorescein staining of the cornea~* Intraocular surgery within 6 months~* Serious hypersensitivity to any components of the study medications or risk from treatment with glaucoma medications, such as severe asthma or emphysema.~* Use of any glucocorticoid by any route. Subject must be washed out of the glucocorticoid for at least 2 weeks before study entry.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Paracetamol and Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 18 to 65 years,~* Patient suffering from chronic pain (for more than 3 months) with the characteristics of peripheral neuropathy and having pain assessed by a numerical scale ≥ 3 for one week, with at least 10 assessments completed,~* Patient agrees with not to take paracetamol, other than the treatment provided as part of the protocol, from inclusion to completion of the study,~* Acceptance to give a written consent.~Exclusion Criteria:~* Patient taking paracetamol daily,~* Patient with a contraindication to paracetamol administration (liver or renal failure, ...),~* Patient with a biological evaluation evaluated by the investigator as not compatible with the trial,~* Patient with a medical and/or surgical history evaluated by the investigator to be not compatible with the trial,~* Patient with drug treatments evaluated by the investigator to be not compatible with the trial,~* Pregnant or nursing woman,~* Patient with a cooperation and an understanding that does not allow for a strict compliance under the conditions set out in the protocol,~* Patient participating in another clinical trial, or being in an exclusion period, or having received a total amount of compensation exceeding 4500 euros over the 12 months preceding the start of the trial,~* Patient benefiting from a legal protection measure (curatorship, guardianship, protection of justice...),~* Patient not affiliated to the French Social Security system,~* Paracetamol intake during wash-out period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paracetamol and placebo comparator (Group 1) (Type: OTHER): Neuropathic pain patients taking either paracetamol or placebo according to the randomization plan
- Paracetamol and placebo comparator (Group 2) (Type: OTHER): Neuropathic pain patients taking either paracetamol (if during period 1 they received placebo) or placebo (if during period 1 they received paracetamol)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory acute myelogenous or lymphoid leukemia.~* Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.~* Chronic myelogenous leukemia in accelerated phase or blast-crisis.~* Chronic myelogenous leukemia in second or subsequent chronic phase~* Recurrent or refractory malignant lymphoma or Hodgkin's disease~* Multiple myeloma at high risk for disease recurrence.~* Chronic lymphocytic leukemia, relapsed or with poor prognostic features.~* Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.~Exclusion Criteria:~* Clinical progression.~* Contra-indications for vaccination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Domperidone to Increase Breastmilk Supply in Mothers With Low Supply

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Women~* healthy women~* inadequate milk supply~* read/speak English~Infants~* healthy term infants (≥ 38 weeks gestational age)~* age ≥ 2wks and ≤3mths~* surpassed birth weight~Exclusion Criteria:~Mother~* cardiac anomalies~* breast or endocrine abnormalities (i.e. breast CA, pituitary adenomas)~* medications contraindicated with domperidone use~* drug or alcohol use~* use of hormonal contraception~Infant~* physical anomalies making breastfeeding difficult (i.e. cleft palate)~* cardiac anomalies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 20 - 79 years~* Diabetes mellitus patients with diabetic polyneuropathy who have pain symptom for 26 weeks prior to the study~* Subjects who are compliant with diary completion~Exclusion Criteria:~* Subjects who have pain from other diseases at the evaluating site~* Subjects who have nerve diseases at the evaluating site~* Subjects with foot ulcer or gangrene

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Low dose group
- 2 (Type: EXPERIMENTAL): Middle dose group
- 3 (Type: EXPERIMENTAL): High dose group
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~For Alzheimer groups without DCR and Alzheimer with DCR:~* patients between 70 and 90 years old~* with mild to moderate Alzheimer's disease (MMSE\> 15/30),~* followed in the CMRR of the University Hospital of Nantes or Angers~* having given their informed consent~For the control group (non-Alzheimer's)~* more patients between 70 and 90 years~* consultant for a subjective memory complaint isolated at the CMRR of Nantes or Angers University Hospital,~* having given their informed consent~Exclusion Criteria:~* Major patients under tutorship, curatorship or safeguard of justice~* Cognitive disorders possibly related to a metabolic or psychiatric cause~* History of prescription of antibiotic treatment in the last month~* History of acute gastrointestinal illness in the last month~* History of hospitalization for an acute medical pathology or for a surgical procedure in the last month

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Alzheimer with rapid DCR (Type: EXPERIMENTAL): None
- Alzheimer without rapid DCR (Type: EXPERIMENTAL): None
- Control (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues